{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:23:39Z","timestamp":1783445019229,"version":"3.54.6"},"reference-count":25,"publisher":"Bioscientifica","issue":"6","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":1627,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Introduction: Primary squamous cell carcinoma (PSCC) of the thyroid is an exceptionally rare malignancy accounting for &amp;lt;1% of all primary thyroid cancers. Therapy is multimodal including surgery, radiotherapy, and chemotherapy but with no consensus for management and therapy. Here, we describe a case of a male patient who presented with a BRAF V600E-mutated PSCC of the thyroid gland showing response to combined dabrafenib and trametinib therapy over a period of &amp;gt;12 months. Case Presentation: A 78-year-old male patient presented with a 3-week history of dysphonia and dyspnoea. Laryngoscopy revealed a mechanical obstruction by a right-sided, subglottical mass, which on cervical ultrasound was highly suggestive of anaplastic thyroid carcinoma. Additional workup including esophagogastroduodenoscopy showed compression of the oesophagus but no oesophageal infiltration by the tumour. Immunohistochemistry displayed CK19-positive cells indicating epithelial origin of the tumour. CK5\/6 and P40 immunohistochemistry confirmed the morphological impression of squamous cell differentiation while staining with thyroid markers TTF-1 and TPO was negative and PAX8 showed a nuclear positive signal. Based on immunohistopathology, presence of TP53 and BRAF V600E mutations, and exclusion of metastatic squamous cell carcinoma of other origin, the diagnosis of a PSCC of the thyroid was established. As an individualized treatment concept, we decided to advocate combined BRAF V600E targeting by the multikinase inhibitors dabrafenib and trametinib. This led to drastic improvement in patient\u2019s quality of life without severe side effects over a period of &amp;gt;12 months. Conclusion: In this case, molecular diagnosis allowed a highly individualized treatment concept with combined dabrafenib and trametinib therapy.<\/jats:p>","DOI":"10.1159\/000518055","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T17:05:12Z","timestamp":1630688712000},"page":"511-516","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-17","source":"Crossref","is-referenced-by-count":6,"title":["Therapeutic Effect of Combined Dabrafenib and Trametinib Treatment of BRAF V600E-Mutated Primary Squamous Cell Carcinoma of the Thyroid: A Case Report"],"prefix":"10.1530","volume":"10","author":[{"given":"Tim","family":"Brandenburg","sequence":"first","affiliation":[{"name":"1Department of Endocrinology, Diabetes and Metabolism, Endocrine Tumour Center at West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany"},{"name":"2Endocrine Tumour Center at West German Cancer Center, Member of ENDO-ERN and EURACAN, University Hospital Essen, University of Duisburg-Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Muchalla","sequence":"additional","affiliation":[{"name":"1Department of Endocrinology, Diabetes and Metabolism, Endocrine Tumour Center at West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany"},{"name":"2Endocrine Tumour Center at West German Cancer Center, Member of ENDO-ERN and EURACAN, University Hospital Essen, University of Duisburg-Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Theurer","sequence":"additional","affiliation":[{"name":"2Endocrine Tumour Center at West German Cancer Center, Member of ENDO-ERN and EURACAN, University Hospital Essen, University of Duisburg-Essen, Essen, Germany"},{"name":"3University Duisburg-Essen, Institute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt Werner","family":"Schmid","sequence":"additional","affiliation":[{"name":"2Endocrine Tumour Center at West German Cancer Center, Member of ENDO-ERN and EURACAN, University Hospital Essen, University of Duisburg-Essen, Essen, Germany"},{"name":"3University Duisburg-Essen, Institute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"F\u00fchrer","sequence":"additional","affiliation":[{"name":"1Department of Endocrinology, Diabetes and Metabolism, Endocrine Tumour Center at West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany"},{"name":"2Endocrine Tumour Center at West German Cancer Center, Member of ENDO-ERN and EURACAN, University Hospital Essen, University of Duisburg-Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2021,9,3]]},"reference":[{"key":"2026070711525018900_ref1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1017\/S0022215110002070","article-title":"Squamous cell carcinoma of the thyroid gland: primary or secondary disease?","volume":"125","author":"Syed","year":"2011","journal-title":"J Laryngol Otol"},{"issue":"5","key":"2026070711525018900_ref2","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1177\/030089160709300522","article-title":"Primary squamous cell carcinoma of the thyroid: immunohistochemical profile and literature review","volume":"93","author":"Fassan","year":"2007  29","journal-title":"Tumori"},{"issue":"1","key":"2026070711525018900_ref3","first-page":"43","article-title":"Thyroid squamous cell carcinoma: a unique type of cancer in World Health Organization classification","volume":"2017","author":"Lam","year":"2020","journal-title":"Case Rep Oncol Med"},{"key":"2026070711525018900_ref4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/838079","article-title":"Primary squamous cell carcinoma of thyroid: a rare entity","volume":"2015","author":"Chavan","year":"2015","journal-title":"Case Rep Pathol"},{"issue":"1","key":"2026070711525018900_ref5","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1758-3284-4-8","article-title":"Primary squamous cell carcinoma of thyroid: a case report and review of literature","volume":"4","author":"Tunio","year":"2012","journal-title":"Head Neck Oncol"},{"key":"2026070711525018900_ref6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ijscr.2017.06.011","article-title":"Primary squamous cell carcinoma of the thyroid: case report and systematic review of the literature","volume":"37","author":"Struller","year":"2017","journal-title":"Int J Surg Case Rep"},{"issue":"5","key":"2026070711525018900_ref7","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/cam4.287","article-title":"Primary squamous cell carcinomas in the thyroid gland: an individual participant data meta-analysis","volume":"3","author":"Cho","year":"2014  1","journal-title":"Cancer Med"},{"key":"2026070711525018900_ref8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/978-981-13-1897-9_4","article-title":"What\u2019s new in thyroid tumor classification, the 2017 World Health Organization classification of tumours of endocrine organs","author":"Tallini","year":"2019","journal-title":"Thyroid FNA Cytol"},{"issue":"2","key":"2026070711525018900_ref9","doi-asserted-by":"crossref","first-page":"E356","DOI":"10.1016\/j.ijrobp.2016.06.1526","article-title":"Association between BRAF V600E mutation and decreased survival in patients locoregionally irradiated for anaplastic thyroid carcinoma","volume":"96","author":"Choi","year":"2016  1","journal-title":"Int J Radiation Oncol Biol Phys"},{"issue":"11","key":"2026070711525018900_ref10","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1210\/jc.2003-030838","article-title":"BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas","volume":"88","author":"Nikiforova","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026070711525018900_ref11","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s12020-016-1080-9","article-title":"Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer","volume":"54","author":"Latteyer","year":"2016  1","journal-title":"Endocrine"},{"issue":"1","key":"2026070711525018900_ref12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer","volume":"36","author":"Subbiah","year":"2018  1","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026070711525018900_ref13","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019  15","journal-title":"N Engl J Med"},{"issue":"10","key":"2026070711525018900_ref14","doi-asserted-by":"crossref","first-page":"153146","DOI":"10.1016\/j.prp.2020.153146","article-title":"Primary squamous cell carcinoma of thyroid with a novel BRAF mutation and High PDL-1 expression: a case report with treatment implications and review of literature","volume":"216","author":"Torrez","year":"2020  1","journal-title":"Pathol Res Pract"},{"issue":"7","key":"2026070711525018900_ref15","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1089\/thy.2018.0060","article-title":"Neoadjuvant BRAF- and immune-directed therapy for anaplastic thyroid carcinoma","volume":"28","author":"Cabanillas","year":"2018  1","journal-title":"Thyroid"},{"issue":"1","key":"2026070711525018900_ref16","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1440-1827.2011.02745.x","article-title":"Primary pure squamous cell carcinoma of the thyroid: report and histogenic consideration of a case involving a BRAF mutation","volume":"62","author":"Ko","year":"2012","journal-title":"Pathol Int"},{"issue":"4","key":"2026070711525018900_ref17","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.prp.2009.05.003","article-title":"Thyroid carcinoma with papillary and squamous features: report of a case with histogenetic considerations","volume":"206","author":"Rausch","year":"2010  15","journal-title":"Pathol Res Pract"},{"issue":"2","key":"2026070711525018900_ref18","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00428-015-1875-8","article-title":"Papillary thyroid carcinoma with extensive squamous dedifferentiation metastatic to the lung: BRAF mutational analysis as a useful tool to rule out tumor to tumor metastasis","volume":"468","author":"Acosta","year":"2016  1","journal-title":"Virchows Arch"},{"issue":"3","key":"2026070711525018900_ref19","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1177\/1066896916674811","article-title":"Metastatic papillary thyroid carcinoma with adjacent BRAF (V600E)-mutated squamous cell carcinoma","volume":"25","author":"Rupani","year":"2017  21","journal-title":"Int J Surg Pathol"},{"issue":"14","key":"2026070711525018900_ref20","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2169\/internalmedicine.52.9310","article-title":"Papillary thyroid carcinoma recurring as squamous cell carcinoma 10 years after total thyroidectomy: lessons from rapidly progressive papillary thyroid carcinoma","volume":"52","author":"Lee","year":"2013  15","journal-title":"Intern Med"},{"issue":"5","key":"2026070711525018900_ref21","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1158\/2159-8290.CD-12-0531","article-title":"Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas","volume":"3","author":"Montero-Conde","year":"2013","journal-title":"Cancer Discov"},{"issue":"22","key":"2026070711525018900_ref22","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1200\/JCO.2010.33.2312","article-title":"Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling","volume":"29","author":"Wagle","year":"2011  1 [ 2021  19]","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026070711525018900_ref23","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1210\/jc.2016-3756","article-title":"Expression of PD-1 and PD-L1 in anaplastic thyroid cancer patients treated with multimodal therapy: results from a retrospective study","volume":"102","author":"Chintakuntlawar","year":"2017  1","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026070711525018900_ref24","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1210\/jc.2015-4227","article-title":"Tumor-infiltrating T Cells and the PD-1 checkpoint pathway in advanced differentiated and anaplastic thyroid cancer","volume":"101","author":"Bastman","year":"2016  1","journal-title":"J Clin Endocrinol Metab"},{"issue":"23","key":"2026070711525018900_ref25","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1200\/JCO.19.02727","article-title":"PD-1 blockade in anaplastic thyroid carcinoma","volume":"38","author":"Capdevila","year":"2020  4","journal-title":"J Clin Oncol"}],"container-title":["European Thyroid Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/518055","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/10\/6\/511\/21968\/etj518055.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/10\/6\/511\/21968\/etj518055.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:28:12Z","timestamp":1783441692000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article\/10\/6\/511\/2772\/Therapeutic-Effect-of-Combined-Dabrafenib-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,3]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000518055","relation":{},"ISSN":["2235-0802","2235-0640"],"issn-type":[{"value":"2235-0802","type":"electronic"},{"value":"2235-0640","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9,3]]}}}